Role of IL28B genotype in older hepatitis C virus-infected patients

Table 1 Association between sustained virological response rates, age and gender in chronic hepatitis C patients treated with standard of care

Ref.	G	Number of	Naive	Age (yr, mean ± SD)/	Formula	SVR rates
		patients		gender (male)
McHutchison et al[17]	1	1016	Yes	47.5 ± 8.1/59.7%	Low-dose PegIFN alpha-2b plus RBV	38.00%
	1	1019	Yes	47.5 ± 7.8/60.2%	Standard-dose PegIFN alpha-2b plus RBV	39.80%
	1	1035	Yes	47.6 ± 8.2/59.2%	PegIFN alpha-2a plus RBV	40.90%
Jeffers et al[18]	1	78 (Black)	Yes	46.3 ± 0.7/72%	PegIFN alpha-2a plus RBV	26.00%
	1	28 (White)	Yes	44.7 ± 1.4/61%	PegIFN alpha-2a plus RBV	39.00%
Bruno et al[19]	1	163	Yes	49.9 ± 11.1/62%	PegIFN alpha-2b plus RBV	41.10%
	1	148	Yes	49.5 ± 11.1/62%	IFN alpha-2b plus RBV	29.30%
Conjeevaram et al[20]	1	196 (African-Americans)	Yes	49.0 ± (45.0, 52.5)/64.8%	PegIFN alpha-2a plus RBV	28.00%
	1	205 (Caucasian-Americans)	Yes	48.0 ± (43.0, 52.0)/65.8%	PegIFN alpha-2a plus RBV	52.00%
Miyauchi et al[21]	1	383	-	55.0 ± 10.9/62%	PegIFN alpha-2b plus RBV	61.80%
Kanda et al[22]	1	127	Yes	56.1 ± 10.7/48.8%	PegIFN alpha-2a plus RBV	56.60%
	1	69	No	59.0 ± 10.1/49.2%	PegIFN alpha-2a plus RBV	39.10%

G: Genotype; IFN: Interferon; SVR: Sustained virological response; RBV: Ribavirin.